Key points are not available for this paper at this time.
BackgroundPrognostic models have been developed using data from a multicentre noncomparative study to forecast the likelihood of a 50% reduction in prostate-specific antigen (PSA50), longer prostate-specific antigen (PSA) progression-free survival (PFS), and longer overall survival (OS) in patients with metastatic castration-resistant prostate cancer receiving 177LuLu-PSMA radioligand therapy. The predictive utility of the models to identify patients likely to benefit most from 177LuLu-PSMA compared with standard chemotherapy has not been established. ObjectiveTo determine the predictive value of the models using data from the randomised, open-label, phase 2, TheraP trial (primary objective) and to evaluate the clinical net benefit of the PSA50 model (secondary objective). Design, setting, and participantsAll 200 patients were randomised in the TheraP trial to receive 177LuLu-PSMA-617 (n = 99) or cabazitaxel (n = 101) between February 2018 and September 2019. Outcome measurements and statistical analysisPredictive performance was investigated by testing whether the association between the modelled outcome classifications (favourable vs unfavourable outcome) was different for patients randomised to 177LuLu-PSMA versus cabazitaxel. The clinical benefit of the PSA50 model was evaluated using a decision curve analysis. Results and limitationsThe probability of PSA50 in patients classified as having a favourable outcome was greater in the 177LuLu-PSMA-617 group than in the cabazitaxel group (odds ratio 6. 36 95% confidence interval CI 1. 69–30. 80 vs 0. 96 95% CI 0. 32–3. 05; p = 0. 038 for treatment-by-model interaction). The PSA50 rate in patients with a favourable outcome for 177LuLu-PSMA-617 versus cabazitaxel was 62/88 (70%) versus 31/85 (36%). The decision curve analysis indicated that the use of the PSA50 model had a clinical net benefit when the probability of a PSA response was ≥30%. The predictive performance of the models for PSA PFS and OS was not established (treatment-by-model interaction: p = 0. 36 and p = 0. 41, respectively). ConclusionsA previously developed outcome classification model for PSA50 was demonstrated to be both predictive and prognostic for the outcome after 177LuLu-PSMA-617 versus cabazitaxel, while the PSA PFS and OS models had purely prognostic value. The models may aid clinicians in defining strategies for patients with metastatic castration-resistant prostate cancer who failed first-line chemotherapy and are eligible for 177LuLu-PSMA-617 and cabazitaxel. Patient summaryIn this report, we validated previously developed statistical models that can predict a response to Lu-PSMA radioligand therapy in patients with advanced prostate cancer. We found that the statistical models can predict patient survival, and aid in determining whether Lu-PSMA therapy or cabazitaxel yields a higher probability to achieve a serum prostate-specific antigen response.
Gafita et al. (Mon,) studied this question.